Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment
Status:
RECRUITING
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.
Phase:
PHASE2
Details
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Collaborators:
Dr. Andrs Gmez de Len Dr. David Gmez Almaguer Dr. Jos Carlos Jaime Perez Dra. Consuelo Mancias Guerra Dra. Michelle Morcos Sandino Dra. Olga Graciela Cat Rodrguez Dra. Perla Colunga Pedraza Marisa Romero Martnez